Novo Nordisk shares new health benefits of Wegovy
諾和諾德公佈 Wegovy 的新健康益處
更新於: 2026年6月7日 上午05:30
Novo Nordisk is reshaping how we view Wegovy, a medication originally known primarily for weight loss.
諾和諾德正在重塑我們看待Wegovy的方式，這是一種最初主要以減重聞名的藥物。
Recent data, including insights from the landmark SELECT trial, reveal that Wegovy offers significant health benefits that extend far beyond shedding pounds.
近期的數據，包括來自具有里程碑意義的SELECT試驗中的洞見，揭示了Wegovy提供的健康益處遠不止於減輕體重。
For patients with obesity and cardiovascular disease, the drug has been shown to reduce the risk of major events like heart attacks and strokes by 20%.
對於患有肥胖症和心血管疾病的患者，該藥物已被證實能將心臟病發作和中風等重大事件的風險降低20%。
Beyond heart health, researchers are discovering that semaglutide—the active ingredient in Wegovy—may help manage various obesity-related comorbidities.
除了心臟健康，研究人員正發現司美格魯肽——Wegovy的活性成分——可能有助於管理各種與肥胖相關的共病症。
These benefits are likely tied to the drug’s ability to reduce systemic inflammation.
這些益處很可能與該藥物降低全身性發炎的能力有關。
Wegovy is increasingly recognized not merely as a weight-loss tool, but as a comprehensive therapy for the interconnected health risks that accompany obesity.
Wegovy日益被認定不僅僅是一種減重工具，而是一種針對伴隨肥胖而來的相互關聯健康風險的綜合治療方案。
This evolution marks a significant milestone in modern metabolic medicine.
這種演變標誌著現代代謝醫學的一個重要里程碑。
